Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Regeneron (REGN – Research Report), KalVista Pharmaceuticals (KALV – Research Report) and Iovance Biotherapeutics (IOVA – Research Report).
Regeneron (REGN)
Robert W. Baird analyst Brian Skorney maintained a Hold rating on Regeneron on September 8 and set a price target of $620.00. The company’s shares closed last Friday at $724.32, close to its 52-week high of $754.67.
According to TipRanks.com, Skorney is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Regeneron with a $735.27 average price target, which is a 3.3% upside from current levels. In a report issued on September 8, Jefferies also upgraded the stock to Hold with a $675.00 price target.
See today’s best-performing stocks on TipRanks >>
KalVista Pharmaceuticals (KALV)
SVB Securities analyst Joseph Schwartz maintained a Buy rating on KalVista Pharmaceuticals on September 8 and set a price target of $45.00. The company’s shares closed last Friday at $15.87.
According to TipRanks.com, Schwartz is ranked 0 out of 5 stars with an average return of
Currently, the analyst consensus on KalVista Pharmaceuticals is a Strong Buy with an average price target of $43.75, implying a 173.4% upside from current levels. In a report issued on September 8, Needham also maintained a Buy rating on the stock with a $38.00 price target.
Iovance Biotherapeutics (IOVA)
In a report released today, Reni Benjamin from JMP Securities reiterated a Buy rating on Iovance Biotherapeutics, with a price target of $25.00. The company’s shares closed last Friday at $11.20.
According to TipRanks.com, Benjamin is ranked 0 out of 5 stars with an average return of
Iovance Biotherapeutics has an analyst consensus of Strong Buy, with a price target consensus of $23.71, representing an 110.4% upside. In a report issued on August 29, Mizuho Securities also maintained a Buy rating on the stock with a $30.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on REGN:
- Australian Stock Market Today – Monday September 12: What You Need to Know
- SVB Securities Issues a Buy Rating on Eli Lilly & Co (LLY)
- Trimble Navigation (TRMB) Gets a Buy from Robert W. Baird
- SVB Securities Keeps Their Hold Rating on Alnylam Pharma (ALNY)
- Robert W. Baird Sticks to Their Buy Rating for Wyndham Hotels & Resorts (WH)
